KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EPS (Weighted Average and Diluted) (2020 - 2025)

Acadia Pharmaceuticals (ACAD) has 8 years of EPS (Weighted Average and Diluted) data on record, last reported at $1.61 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 87.21% year-over-year to $1.61; the TTM value through Dec 2025 reached $2.3, up 69.12%, while the annual FY2025 figure was $2.3, 69.12% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $1.61 in Q4 2025 per ACAD's latest filing, up from $0.42 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.61 in Q4 2025 and bottomed at -$0.7 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.04, with a median of -$0.04 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 135.29% in 2023, then skyrocketed 1900.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.27 in 2021, then increased by 3.7% to -$0.26 in 2022, then surged by 207.69% to $0.28 in 2023, then soared by 207.14% to $0.86 in 2024, then skyrocketed by 87.21% to $1.61 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $1.61 in Q4 2025, $0.42 in Q3 2025, and $0.16 in Q2 2025.